CD22-directed Immunoconjugate class drugs

1 result

Besponsa (inotuzumab ozogamicin)

(inotuzumab ozogamicin)
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Usage: BESPONSA is indicated for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients aged 1 year and older.